ReviewInflammopharmacology2026
Targeted delivery of curcumin based on nanocarriers: potential therapeutic strategies for noninfectious arthritis.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmaceutical Compounding as a Pillar of Personalized Oncology: Current Applications, Emerging Technologies, and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Arthritis, an acute inflammatory disease affecting single or multiple joints, causes irreversible damage to cartilage and bone, leading to substantial pain and economic burden. Current treatments lack specificity. Curcumin, with its anti-inflammatory and antioxidant properties, shows promise in arthritis treatment, yet its poor water solubility and low bioavailability hinder clinical use. This study investigates the efficacy of a nanocarrier-based curcumin delivery system for non-infectious arthritis. Four types of nanocarriers-liposomes, biomolecule-based nanoparticles, nanoemulsions, and improved nanocarriers-are reviewed for their ability to target curcumin delivery. These nanocarriers improve curcumin's therapeutic effects by enhancing pharmacokinetics, prolonging circulation, and protecting against degradation. Demonstrating potential in various non-infectious arthritis types, including ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, and gout, this study underscores the efficacy of nanocarrier-based curcumin delivery systems in reducing inflammation, modulating immune responses, and alleviating disease symptoms. Future research should focus on optimizing nanocarrier design for increased bioavailability and conducting more clinical trials to validate safety and effectiveness in humans.
Indexed as
Identifiers
41784926What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.